The merger has closed and BLFS is now a wholly owned subsidiary of Repligen. BLFS shares will cease trading; former BLFS shareholders now hold RGEN shares and cash. Monitor the two pending shareholder lawsuits in New York state court for any post-closing litigation seeking rescission or damages, though the deal has already closed.
Price Chart
Executive Summary
BioLife Solutions (BLFS) has been acquired by Repligen Corporation (RGEN) in a cash-and-stock merger that closed on October 6, 2026. Each BLFS share converted into $11.25 cash plus 0.1442 RGEN shares, and BLFS common stock has been delisted from Nasdaq. All BLFS directors and named executive officers resigned, and the company's charter and bylaws were amended to reflect its new status as a wholly owned subsidiary of Repligen.
Key Facts
- Merger closed on October 6, 2026; BLFS shareholders received $11.25 cash plus 0.1442 RGEN shares per BLFS share
- Stockholder vote on October 5, 2026 approved the merger: 40,910,337 FOR, 83,451 AGAINST, 807 abstain
- BLFS common stock delisted from Nasdaq effective October 6, 2026; Form 15 to be filed to terminate SEC reporting
- All BLFS directors (Roderick de Greef, Cathy Coste, Amy DuRoss, Rachel Ellingson, Joydeep Goswami, Tony Hunt, Tim Moore) and all named executive officers resigned
- Certificate of incorporation and bylaws amended and restated to reflect new ownership structure
- Two shareholder lawsuits filed in New York state court seeking to enjoin the merger; BioLife and Repligen are defending
Financial Impact
BLFS shareholders receive $11.25 cash plus 0.1442 RGEN shares per share; BLFS stockholders will own approximately 11.1% of combined company per prior proxy disclosure
Risk Factors
- Two shareholder lawsuits filed in New York state court seek to enjoin or rescind the merger; outcome uncertain
- Post-closing appraisal rights for dissenting shareholders under Delaware law
- Integration risk for Repligen in absorbing BioLife's operations and personnel
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-415012 |
| Document: d753652d8k.htm | 0001193125-26-415012 |
| Document: d753652dex31.htm | 0001193125-26-415012 |
| Document: 0001193125-26-415012-index-headers.html | 0001193125-26-415012 |
| Document: 0001193125-26-415012-index.html | 0001193125-26-415012 |
| Document: 0001193125-26-415012.txt | 0001193125-26-415012 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 15-12G | — | awaiting T+20 | — | — |
Oct 13, 2026 14d ago | EFFECT | — | awaiting T+20 | — | — |
Oct 13, 2026 14d ago | EFFECT | — | awaiting T+20 | — | — |
Oct 6, 2026 20d ago | 8-K | $39.00 | awaiting T+20 | — | — |
Sep 30, 2026 26d ago | 425 | $38.85 | awaiting T+20 | — | — |
Sep 30, 2026 26d ago | DEFA14A | $38.85 | awaiting T+20 | — | — |
Sep 24, 2026 4w ago | SC 13G | $38.58 | awaiting T+20 | — | — |
Sep 4, 2026 7w ago | DEFM14A | $35.38 $38.61 | ▲ +9.13% | ▲ +7.42% | — |
Jun 3, 2026 20w ago | 8-K | $27.25 $28.11 | ▲ +3.16% | ▲ +4.16% | — |
Apr 28, 2026 25w ago | 10-K/A | $19.99 $25.25 | ▲ +26.31% | ▲ +20.26% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers